EGFR and ductal breast carcinoma in situ: This is in contrast to a study by Livasy et al (2007), who, in an analysis of 245 pure DCIS cases, identified 8% as basal (defined as ER−, Her2−, EGFR+ and/or CK5/6+) and a further 6% fell into the TN category.